Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 30, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted an abstract for presentation at the EASL 2016 annual meeting to be held April 13 - 17, 2016, in Barcelona, Spain.
“We are pleased to present data on our core protein/capsid assembly inhibitor program, which supports our strategy of attacking HBV through multiple different mechanisms of action,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “Our lead HBV product candidate, ARB-1467, is in an ongoing Phase II study in chronically infected HBV patients. In addition, we are advancing our other HBV programs to support initiation of clinical combination studies in 2017.”
Poster Presentation
- Title: "In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small Molecule Inhibitor of Hepatitis B Virus Capsid Assembly”
- Date: Thursday, April 14, 2016
- Abstract Number: THU-198
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: [email protected]
Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: [email protected]
Media
Please direct all media inquiries to: [email protected]
